Skye Bioscience, Inc. — Director's Dealing 2021

Oct 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Skye Bioscience, Inc. (SKYE)
CIK: 0001516551
Period of Report: 2021-10-04

Reporting Person: Arsenault Kaitlyn Melanie (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-04	Employee Stock Option (Right to Buy)	$0.09	A	1600000	Acquired	2031-10-04	Common Stock (1600000.0)	Direct

Footnotes

F1: 10% of the Options shall vest on October 4, 2021 (the "Vesting Start Date") and the remaining 90% of the Options will vest in equal semi-annual installments over four annual periods.